Search - tctmd.com

Displaying 301 - 320 of 1046

Sort: Relevancy | Date

Presentation TCT 2021

Review of Bicuspid TAVR Data in Intermediate and High-Risk Patients

Presenter: Hasan Jilaihawi

November 04, 2021

Presentation TCT 2021

Implant Strategies for Optimizing Procedural Outcomes in Bicuspid TAVR

Presenter: Didier Tchetche

November 04, 2021

Presentation TCT 2021

Lessons From the CTA: For Bicuspid It’s About Calcium Not About Sievers

Presenter: Raj Makkar

November 04, 2021

Presentation TCT 2021

TAV in TAV: The First TAVR Matters

Presenter: Janarthanan Sathananthan

November 04, 2021

Presentation TCT 2021

Bioprosthetic Valve Fracture: All or Some, When, and How?

Presenter: Adnan Chhatriwalla

November 04, 2021

Presentation TCT 2021

Mitigating Coronary Obstruction: Snorkel or Slice

Presenter: Jaffar Khan

November 04, 2021

Presentation TCT 2021

Bioprosthetic Valve Failure: Redo SAVR or ViV TAVR?

Presenter: Kendra Grubb

November 04, 2021

Presentation TCT 2021

FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report: Final 5 Year Clinical Outcomes

Presenter: Matthias Lutz

November 04, 2021

Presentation TCT 2021

Prasugrel De-escalation Therapy After Complex Percutaneous Coronary Intervention in Acute Coronary Syndrome: A Subgroup Analysis of the HOST-REDUCE-POLYTECH-ACS Randomized Clinical Trial

Presenter: Doyeon Hwang

November 04, 2021

Presentation TCT 2021

Debate 2: Con – The ISCHEMIA Results Apply to All Revascularization; We All Need to Reconsider Our Approach

Presenter: Sripal Bangalore

November 04, 2021

Presentation TCT 2021

Debate 2: Pro – The ISCHEMIA Trial Results Do Not Apply to CABG; Our Outcomes Are Different!

Presenter: Mario Gaudino

November 04, 2021

Presentation TCT 2021

Debate 1: Con – Anatomy First; NICE Guidelines Got It Right

Presenter: Nick Curzen

November 04, 2021

Presentation TCT 2021

HALT: Long-Term Clinical Impact of Hypoattenuating Leaflet Thickening After TAVR

Presenter: Santiago Garcia

November 04, 2021

Presentation TCT 2021

Debate 1: Pro – Functional Testing Matters; We Need to Follow the ACC/AHA Guidelines

Presenter: Raymond Kwong

November 04, 2021

Presentation TCT 2021

Outcomes of Repeat TAVR According to the Initial and Subsequent TAVR Type

Presenter: Uri Landes

November 04, 2021

Presentation TCT 2021

What’s Next for Chronic Coronary Syndromes? Upcoming Clinical Trials

Presenter: Christopher Rajkumar

November 04, 2021

News Daily News

Intravascular Lithotripsy May Facilitate TAVI in Patients With PAD

L.A. McKeown

November 04, 2021

Presentation TCT 2021

TCT 676: Emergent Thrombectomy of Right Ventricular Thrombus and Massive Pulmonary Emboli using Inari FlowTriever

Presenter: Qasim Jehangir

November 04, 2021

Presentation TCT 2021

TCT 675: Massive Pulmonary Embolism Requiring VA ECMO, Percutaneous Thrombectomy, and Ultimately Surgical Embolectomy

Presenter: Robert Zilinyi

November 04, 2021

Presentation TCT 2021

Outcomes of Repeat TAVR With Balloon-Expandable Sapien 3/Ultra Valves

Presenter: Raj Makkar

November 04, 2021

Advertisement

Review of Bicuspid TAVR Data in Intermediate and High-Risk Patients

Implant Strategies for Optimizing Procedural Outcomes in Bicuspid TAVR

Lessons From the CTA: For Bicuspid It’s About Calcium Not About Sievers

TAV in TAV: The First TAVR Matters

Bioprosthetic Valve Fracture: All or Some, When, and How?

Mitigating Coronary Obstruction: Snorkel or Slice

Bioprosthetic Valve Failure: Redo SAVR or ViV TAVR?

FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report: Final 5 Year Clinical Outcomes

Prasugrel De-escalation Therapy After Complex Percutaneous Coronary Intervention in Acute Coronary Syndrome: A Subgroup Analysis of the HOST-REDUCE-POLYTECH-ACS Randomized Clinical Trial

Debate 2: Con – The ISCHEMIA Results Apply to All Revascularization; We All Need to Reconsider Our Approach

Debate 2: Pro – The ISCHEMIA Trial Results Do Not Apply to CABG; Our Outcomes Are Different!

Debate 1: Con – Anatomy First; NICE Guidelines Got It Right

HALT: Long-Term Clinical Impact of Hypoattenuating Leaflet Thickening After TAVR

Debate 1: Pro – Functional Testing Matters; We Need to Follow the ACC/AHA Guidelines

Outcomes of Repeat TAVR According to the Initial and Subsequent TAVR Type

What’s Next for Chronic Coronary Syndromes? Upcoming Clinical Trials

Intravascular Lithotripsy May Facilitate TAVI in Patients With PAD

TCT 676: Emergent Thrombectomy of Right Ventricular Thrombus and Massive Pulmonary Emboli using Inari FlowTriever

TCT 675: Massive Pulmonary Embolism Requiring VA ECMO, Percutaneous Thrombectomy, and Ultimately Surgical Embolectomy

Outcomes of Repeat TAVR With Balloon-Expandable Sapien 3/Ultra Valves

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content